Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats

被引:48
|
作者
Soga, Mayako
Kamal, Fadia A.
Watanabe, Kenichi
Ma, Meilei
Palaniyandi, Suresh
Prakash, Paras
Veeraveedu, Punniyakoti
Mito, Sayaka
Kunisaki, Megumi
Tachikawa, Hitoshi
Kodama, Makoto
Aizawa, Yoshifusa
机构
[1] Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Dept Clin Pharmacol, Niigata, Japan
[2] Niigata Univ, Grad Sch Med & Dent Sci, Dept Med 1, Niigata, Japan
关键词
anthracycline; cardiomyopathy; angiotensin receptor blocker; apoptosis; Fas-L; SERCA2;
D O I
10.1016/j.ijcard.2005.08.061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Daunorubicin is an anthracycline anti-tumor agent; anthracycline chemotherapy in cancer can cause severe cardiomyopathy leading to a frequently fatal congestive heart failure; the first-line treatment is diuretics and digoxin. Recently, angiotensin-converting enzyme inhibitors have been shown to be effective in the treatment of such toxicity. The purpose of this study was to investigate the effects of angiotensin II type-1 receptor antagonist (candesartan) in a rat model of daunorubicin-induced cardiomyopathy. Methods: Rats were treated with a cumulative dose of 9 mg/kg body weight daunorubicin (i.v.). 28 days later, after the development of cardiomyopathy, animals were randomly assigned to candesartan-treated (5 mg/kg/day, p.o.) or vehicle-treated groups; age-matched normal rats were used as the control group. Candesartan treatment was continued for 28 days. Hemodynamic and echocardiographic parameters were measured, cardiac protein and mRNA were analyzed, and histopathological analyses of myocardial fibrosis, cell size and apoptosis were conducted. Results: Following cardiomyopathy, left ventricular end diastolic pressure and left ventricular systolic dimension were significantly elevated; while % fractional shortening and Doppler E/A ratio were significantly reduced. Cardiomyopathic hearts showed significant increases in % fibrosis, % apoptosis, and myocyte diameter/body weight ratio; candesartan treatment reversed these changes. Fas-L protein overexpression in myopathic hearts was significantly suppressed by treatment with candesartan. Moreover, SERCA2 rnRNA and protein expression were both down-regulated in myopathic hearts and restored to normal by candesartan treatment, significantly. Conclusions: Our findings suggest that candesartan treatment significantly improved the left ventricular function and reversed the myocardial pathological changes investigated in this model of daunorubicin-induced cardiomyopathy; suggesting its potentials in limiting daunorubicin cardiotoxicity. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:378 / 385
页数:8
相关论文
共 50 条
  • [31] Beneficial effects of candesartan, an angiotensin II type I receptor blocker, on β-cell function and morphology in db/db mice
    Shao, Jiaqing
    Iwashita, Noseki
    Ikeda, Fuki
    Ogihara, Takeshi
    Uchida, Toyoyoshi
    Shimizu, Tomoaki
    Uchino, Hiroshi
    Hirose, Takahisa
    Kawamori, Ryuzo
    Watada, Hirotaka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 344 (04) : 1224 - 1233
  • [32] Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease
    Kondo, J
    Sone, T
    Tsuboi, H
    Mukawa, H
    Morishima, I
    Uesugi, M
    Kona, T
    Kosaka, T
    Yoshida, T
    Numaguchi, Y
    Matsui, H
    Murohara, T
    Okumura, K
    AMERICAN HEART JOURNAL, 2003, 146 (06)
  • [33] Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan
    Shin-ichiro Miura
    Atsutoshi Okabe
    Yoshino Matsuo
    Sadashiva S Karnik
    Keijiro Saku
    Hypertension Research, 2013, 36 : 134 - 139
  • [35] The Angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer
    Okazaki, Mitsuyoshi
    Fushida, Sachio
    Harada, Shinichi
    Tsukada, Tomoya
    Kinoshita, Jun
    Oyama, Katsunobu
    Tajima, Hidehiro
    Ninomiya, Itasu
    Fujimura, Takashi
    Ohta, Tetsuo
    CANCER LETTERS, 2014, 355 (01) : 46 - 53
  • [36] Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4–5 chronic kidney disease
    Yoshifuru Tamura
    Masahiro Kosuga
    Masahiro Yamashita
    Satoru Tomioka
    Michiko Sasaki
    Tomoyuki Hikita
    Hideaki Nakajima
    Kenichiro Kojima
    Shunya Uchida
    Clinical and Experimental Nephrology, 2008, 12 : 256 - 263
  • [37] Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats
    Sari, Flori R.
    Arozal, Wawaimuli
    Watanabe, Kenichi
    Harima, Meilei
    Veeravedu, Punniyakoti T.
    Thandavarayan, Rajarajan A.
    Suzuki, Kenji
    Arumugam, Somasundaram
    Soetikno, Vivian
    Kodama, Makoto
    PHARMACEUTICALS, 2011, 4 (03): : 551 - 566
  • [38] Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan
    Tsuruoka, S
    Wakaumi, M
    Ioka, T
    Yamamoto, H
    Ando, H
    Sugimoto, K
    Fujimura, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (02) : 204 - 207
  • [39] Combined effects of calcium channel blocker and angiotensin II type 1 receptor blocker in hypertensive Dahl rats
    Yao, K
    Sonoda, R
    Ina, Y
    Ohno, T
    Sato, H
    Suzuki, K
    JOURNAL OF HYPERTENSION, 2002, 20 : S48 - S48
  • [40] Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats
    Yamada, T
    Kuno, A
    Masuda, K
    Ogawa, K
    Sogawa, M
    Nakamura, S
    Ando, T
    Sano, H
    Nakazawa, T
    Ohara, H
    Nomura, T
    Joh, T
    Itoh, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (01): : 17 - 23